AXSMライブシグナル | Getagraph.comで利益を最大化

売る 4381 min ago

@ $71.95

発行日: 27 4月 2024 @ 00:43

リターン: 3.06%

前回のシグナル: 4月 26 - 00:35

前回のシグナル: 買う

リターン: 2.07 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...

Stats
本日の出来高	259 660
平均出来高	721 738
時価総額	3.51B
EPS	$0 ( 2024-02-20 )
次の収益日	( $-1.210 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.07
ATR14	$1.997 (2.69%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Jacobson Mark L.	Buy	24 662	Common Stock
2024-04-01	Jacobson Mark L.	Sell	24 662	Stock Option (Right to Buy)
2024-04-01	Jacobson Mark L.	Sell	24 662	Common Stock
2024-03-14	Jeffs Roger	Buy	16 976	Common Stock
2024-03-14	Jeffs Roger	Buy	13 000	Common Stock

INSIDER POWER
55.14
Last 99 transactions
Buy: 2 269 939 \| Sell: 680 650

ボリューム相関

長: 0.45 (neutral)

短: -0.98 (very strong negative)

Signal:(48) Neutral

Axsome Therapeutics Inc 相関

10 最も正の相関
MMAC	0.888
BOCH	0.879
MIRM	0.876
RNEM	0.87
BATRA	0.869
SINO	0.866
BATRK	0.86
VIRI	0.858
LMRKO	0.854
RAM	0.851

10 最も負の相関
APOP	-0.937
RMRM	-0.915
TDAC	-0.893
MAGS	-0.891
CMLF	-0.868
BHTG	-0.861
VTRU	-0.848
GAINL	-0.847
TRIT	-0.845
SSTI	-0.836

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Axsome Therapeutics Inc 相関 - 通貨/商品

0.13
( neutral )

0.48
( neutral )

0.00
( neutral )

0.20
( neutral )

-0.80
( moderate negative )

-0.07
( neutral )

Axsome Therapeutics Inc 財務諸表

Annual	2023
収益:	$270.60M
総利益:	$237.70M (87.84 %)
EPS:	$-5.27

FY	2023
収益:	$270.60M
総利益:	$237.70M (87.84 %)
EPS:	$-5.27

FY	2022
収益:	$50.04M
総利益:	$44.84M (89.61 %)
EPS:	$-4.86

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.47

Financial Reports:

No articles found.

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.